Skip to main content

Day: August 11, 2023

Guardian Capital Group Limited (TSX: GCG; GCG.A) Announces 2023 Second Quarter Operating Results

TORONTO, Aug. 11, 2023 (GLOBE NEWSWIRE) — All per share figures disclosed below are stated on a diluted basis.         For the periods ended June 30, Three months   Six months  ($ in thousands, except per share amounts)   2023     2022     2023   2022      restated   restated         Net revenue $ 61,833   $ 50,056   $ 116,326 $ 101,878  Operating earnings   17,038     11,404     28,278   24,910  Net gains (losses)   (3,736 )   (91,545 )   14,398   (101,294 )Net earnings (loss) from continuing operations   11,532     (73,463 )   37,974   (73,239 )Net earnings from discontinued operations   —     5,239     553,743   10,830  Net earnings (loss)   11,532     (68,224 )   591,717   (62,409 )                  EBITDA (1) $ 23,199   $ 16,158   $ 40,570 $ 33,661  Adjusted...

Continue reading

Constellation Software Inc. Announces Results for the Second Quarter Ended June 30, 2023 and Declares Quarterly Dividend

TORONTO, Aug. 11, 2023 (GLOBE NEWSWIRE) — Constellation Software Inc. (TSX:CSU) (“Constellation” or the “Company”) today announced its financial results for the second quarter ended June 30, 2023 and declared a $1.00 per share dividend payable on October 11, 2023 to all common shareholders of record at close of business on September 20, 2023. This dividend has been designated as an eligible dividend for the purposes of the Income Tax Act (Canada). Please note that all dollar amounts referred to in this press release are in U.S. Dollars unless otherwise stated. The following press release should be read in conjunction with the Company’s Unaudited Condensed Consolidated Interim Financial Statements for the three and six months ended June 30, 2023 and the accompanying notes, our Management Discussion and Analysis for the three and...

Continue reading

Barnwell Industries, Inc. Reports Third Quarter and Nine Months Ended June 30, 2023 Results

Production of all Products Increased over the Prior Year’s Third Quarter Company Declares Cash Dividend HONOLULU, Aug. 11, 2023 (GLOBE NEWSWIRE) — Barnwell Industries, Inc. (NYSE American: BRN) today reported net losses of $717,000, $0.07 per share, and $865,000, $0.09 per share, for the three and nine months ended June 30, 2023, respectively, as compared to net earnings of $2,531,000, $0.25 per share, and $5,656,000, $0.59 per share, for the three and nine months ended June 30, 2022, respectively. Mr. Alexander C. Kinzler, Chief Executive Officer of Barnwell, commented, “Our loss for the quarter was a result of a decline in prices of all products; oil, natural gas, and natural gas liquids which decreased 37%, 72%, and 46%, respectively, as compared to last year’s three months ended June 20, 2022 together with a decline in land...

Continue reading

Insight Acquisition Corp. and Avila Energy Corporation announce they have mutually agreed to terminate their Business Combination Agreement

NEW YORK and CALGARY, Alberta, Aug. 11, 2023 (GLOBE NEWSWIRE) — Insight Acquisition Corp. (NASDAQ: INAQ) and Avila Energy Corporation (CSE:VIK, OTCM:PTRVF and FRA:6HG0), announced today that on August 10, 2023, they mutually agreed to terminate, effective immediately, their previously announced Business Combination Agreement by and among Insight Acquisition Corp. (“Insight Acquisition”), Avila Amalco Sub Inc. and Avila Energy Corporation (“Avila”), dated as of April 3, 2023 (the “BC Agreement”). As part of the termination of the BC Agreement, Avila has agreed to pay Insight US$300,000 as partial reimbursement of its costs relating to the BC Agreement prior to April 1, 2024. “Due primarily to the changes that have occurred in the SPAC market and the difficulties in arranging financing, Avila and Insight have determined that now...

Continue reading

ReWalk Robotics Announces Closing of Acquisition of AlterG

Combined Company Expected to Expand Access for Patients to Innovative Rehabilitation Technologies for Use in Clinics and the Home Charles Remsberg Appointed Chief Sales Officer at ReWalk Robotics MARLBOROUGH, Mass. and BERLIN and YOKNEAM ILLIT, Israel, Aug. 11, 2023 (GLOBE NEWSWIRE) — ReWalk Robotics Ltd. (Nasdaq: RWLK) (“ReWalk” or “the Company”), a leading provider of innovative technologies that enable mobility and wellness in rehabilitation and daily life for individuals with neurological conditions, today announced closing of the previously announced acquisition of AlterG, Inc. (“AlterG”), a leading innovator and leading provider of Anti-Gravity systems for use in physical and neurological rehabilitation. ReWalk paid a purchase price of approximately $19 million in cash (subject to customary adjustments for net working capital,...

Continue reading

Bridgeline Announces Financial Results for the Third Quarter of Fiscal 2023

WOBURN, Mass., Aug. 11, 2023 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a marketing software solutions provider, today announced financial results for its fiscal third quarter ended June 30, 2023. “Bridgeline’s core products are growing by over 15% CAGR led by HawkSearch which signed over $1 million in new customer contracts this quarter,” said Ari Kahn, Bridgeline’s President and Chief Executive Officer. “Our core products have grown to over 44% of our overall revenue and will begin to dominate our topline as they surpass our legacy products which declined in revenue this year.” Financial Highlights – Third Quarter of Fiscal Year 2023Total revenue was $3.9 million, compared to $4.2 million in the prior year period. Subscription and licenses revenue was $3.2 million, compared to $3.4 million in the prior year...

Continue reading

Jasper Therapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update

First Patient Dosed in Phase 1 trial of Briquilimab in Lower-Risk Myelodysplastic Syndrome Strengthened the Board of Directors and Management Team with Multiple AppointmentsREDWOOD CITY, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a biotechnology company focused on development of briquilimab, a novel antibody therapy targeting c-Kit (CD117) to address diseases such as chronic spontaneous urticaria, lower to intermediate risk myelodysplastic syndromes (LR-MDS) as well as novel stem cell transplant conditioning regimes, today announced results for the fiscal quarter ended June 30, 2023, and provided a business update. “During our second quarter, we continued our preparations to begin a study in chronic spontaneous urticaria, which we anticipate initiating in the coming months,” said...

Continue reading

Entera Bio Announces Q2 2023 Financial Results and Corporate Updates

JERUSALEM, Aug. 11, 2023 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides and therapeutic proteins, today reported corporate updates and financial results for the second quarter ended June 30, 2023. “In the last year, we have successfully focused our resources to drive value across three main pillars: (1) moving our EB613 program along the right path to a Phase 3 registrational study, (2) developing a potential new generation for EB612 and (3) expanding our technological capabilities and platform. Our 2022 R&D plan resulted in pre-clinical validation of proprietary new generations of our oral peptide delivery platform. These are primarily designed to modify pharmacokinetic (PK)/ pharmacodynamic (PD) parameters, optimize bioavailability and...

Continue reading

Volcon ePowersports Reports Second Quarter 2023 Operational and Financial Results

AUSTIN, Texas, Aug. 11, 2023 (GLOBE NEWSWIRE) — Volcon Inc. (NASDAQ: VLCN) (“Volcon” or the “Company”), the first all-electric, off-road powersports company, today reported its operational highlights and financial results for the second quarter of 2023. Company Highlights:As of June 30, 2023, we have 142 dealers Taken delivery of our first eight Stag validation units in 2023 that include our custom suspension parts in addition to the GM propulsion components and expect to launch the Stag to dealers in the fourth quarter of 2023 Have taken pre-orders for the Stag of more than $115 million of expected revenue if all orders are fulfilled1 Grunt EVO launch expected in the third quarter of 2023 and Runt LT launch expected in the fourth quarter of 2023The Company’s US dealer count has remained consistent with the count as of...

Continue reading

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

– Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 – Appointment of Kate McKinley as Chief Business Officer – Presentation of three abstracts on RT-102 and RT-112 at the Endocrine Society Annual Conference and selection as winner of Presidential Poster Competition in its category for exceptional scientific work on RT-102 – Presentation of late-breaking abstract on oral delivery of GLP-1 agonist at American Diabetes Association’s Scientific Sessions – Plan to initiate Phase 2 study for RT-102 and Phase 1 study for RT-111 in 2H of 2023 SAN JOSE, Calif., Aug. 11, 2023 (GLOBE NEWSWIRE) — Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delivery of biologics...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.